



THE 29TH  
ANNUAL  
CONFERENCE

# CONFERENCE AGENDA



MARS DISCOVERY DISTRICT  
SEPTEMBER 22-23, 2025

## FROM CHALLENGE TO CHANGE: DRIVING PROGRESS IN CANADA'S HEALTHCARE LANDSCAPE

**MaRS Discovery District**

101 College St, Toronto, ON M5G 0A3



LEARN MORE



[admin@capt-actp.ca](mailto:admin@capt-actp.ca)

# *Message from* **OUR PRESIDENT**

On behalf of the Canadian Association for Population Therapeutics (CAPT), it is my pleasure to welcome you to our Annual Conference. This year's theme, *From Challenge to Change: Driving Progress in Canada's Healthcare Landscape*, reflects both the urgency and the opportunity we face as a community committed to improving health outcomes through evidence, innovation, and collaboration.

Over the past year, Canada's healthcare system has continued to navigate complex challenges, from evolving population needs and system pressures to the rapid pace of technological and policy change. Yet, within these challenges lies the potential for transformation. CAPT's mission has always been to bring together diverse voices from across the therapeutic and policy spectrum to spark dialogue, share insights, and drive meaningful change.

This conference is a testament to that mission. Over the next few days, you'll engage with leading researchers, policymakers, industry experts, and patient advocates who are shaping the future of population therapeutics. Through keynote presentations, panel discussions, and interactive sessions, we'll explore how data-driven approaches, equitable access, and patient-centered care can help us move from reactive solutions to proactive strategies.

Whether you are joining us for the first time or are a long-standing member of the CAPT community, we invite you to take full advantage of the opportunities to connect, learn, and contribute. Your participation is vital to advancing our shared goals and ensuring that Canada's healthcare landscape continues to evolve in ways that are impactful, evidence-based, and sustainable.

Thank you for being part of this journey. Together, let's turn challenge into change.

**ADAM HAYNES**  
CAPT-ACTP PRESIDENT

# Conference OVERVIEW

Welcome to the 2025 CAPT-ACTP Conference! We're grateful to have you with us and look forward to a great event together. This year's conference's theme is "From Challenge to Change: Driving Progress in Canada's Healthcare Landscape". With theme in mind, our team and partners brought together leading voices from across the healthcare spectrum to address some of the most pressing challenges, and promising opportunities, shaping the future of health in Canada. Over two days, attendees will engage with a rich and diverse set of sessions designed to foster dialogue, spark innovation, and promote evidence-based decision-making across the system.

The program features eight expert-led panels that delve into a range of timely topics, including advancements in health technology assessment and pharmacoeconomics, novel approaches to cancer care, and our healthcare system's readiness. These sessions are designed to not only highlight current developments but also encourage cross-sector discussions among policymakers, researchers, industry stakeholders, and consultants.

A major highlight of Day 1 is our keynote presentation by Dr. Dean Regier, a leading expert in health economics and outcomes research. His talk will explore how to better assess treatments throughout their life cycle, setting the tone for the discussions to follow. Later that same day, we are proud to feature a dedicated session showcasing student research first through selected high-ranking oral presentations followed by one largest poster presentation session ever. This platform provides emerging scholars the opportunity to share their work with a national audience, while offering attendees a glimpse into the next generation of health outcomes researchers.

With its strong emphasis on interdisciplinary perspectives and actionable insights, the conference program reflects our ongoing commitment to driving progress, even in the face of complex healthcare challenges. The CAPT Scientific Program Committee would also like to thank our partners, without whose support and collaboration, this year's conference would not be possible.

We look forward to the thought-provoking conversations, collaborative spirit, and forward-thinking ideas that this year's agenda is sure to inspire.

**JASON R. GUERTIN & ADAM HAYNES**  
CAPT-ACTP SCIENTIFIC PROGRAM COMMITTEE  
CO-CHAIRS

## Session Sponsors





MONDAY, SEPTEMBER 22, 2025

**7:00AM – 8:30AM**     **Registration & Breakfast**  
*Lower Concourse Auditorium Foyer*

**8:30AM – 8:45AM**     **Welcome to the 2025 CAPT-ACTP Conference**  
**Adam Haynes**, CAPT-ACTP President  
*Lower Concourse Auditorium*

**8:45AM – 9:30AM**     **Transforming Health: Life Cycle Assessment for Learning Healthcare**  
**Dr. Dean Regier**, Senior Scientist, BC Cancer Research Institute

**Keynote Overview:** In an era where innovative therapies are entering the market with increasingly limited clinical and economic evidence, the challenge of making informed reimbursement decisions is growing more complex. To navigate this uncertainty, Canada’s healthcare system must evolve into a learning system—one that continuously generates, integrates, and applies data across the life cycle of health technologies. In this keynote address, Dr. Dean Regier, Director of the University of British Columbia’s Academy of Translational Medicine and Senior Scientist at BC Cancer, will explore how life cycle assessment can serve as a data-driven framework to support more adaptive, transparent, and evidence-informed decision-making. Join us on Monday, September 22 as we open the conference with this timely and thought-provoking session that speaks directly to the heart of transforming healthcare through better data.

**9:30AM – 10:30AM**     **Modernizing Market Access: Evolving Pharmacoeconomic Methodologies in Canadian HTA**  
*Moderated by Shoghag Khoudigian, Associate Principal, IQVIA*  
*Panelists:*

- **Yulia Privolnev**, Senior Manager, Market Access, Daiichi Sankyo
- **Alex Haines**, Acting Director, Canada’s Drug Agency
- **Lisa Machado**, Executive Director & Founder, Canadian CML Network
- **Jason R. Guertin**, Associate Professor, Université Laval

**Session Overview:** As Canada’s pharmaceutical landscape evolves, pharmacoeconomic (PE) analysis is becoming central to market access strategies. With the launch of the Health Economics Methods Advisory (HEMA) initiative, Canada is not only modernizing its domestic HTA processes but also contributing to the development of global standards. This interactive panel session will explore how PE methodologies are evolving in response to new evidence types such as real-world evidence (RWE), personalized medicine, and rare diseases. It will also highlight the use of AI, advanced modeling tools (e.g., R), and the growing role of clinician and patient input in HTA reviews. The discussion will set the stage with key shifts shaping Canadian HTA, including time-limited reimbursement, equity, and global alignment.

**10:30AM – 11:00AM**     **Morning Break**

**11:00AM – 12:00PM**     **Accelerating Patient Access: Addressing Gaps in Implementation Readiness**  
*Moderated by Dr. Judith Glennie, President, J.L. Glennie Consulting Inc.*  
*Panelists:*

- **Don Husereau**, Adjunct Professor of Medicine, The University of Ottawa
- **Robert Bick**, Health Policy Consultant, CanCertainty
- **Dr. Sandy Sedhev**, Medical Oncologist, The Ottawa Hospital Cancer Centre
- **Jennifer Smyth**, Interim Regional Vice President, Hamilton Health Sciences/Ontario Health- Cancer Care Ontario

**Session Overview:** To discuss solutions that will enable health systems to take a more proactive approach to implementation planning for complex cancer and other therapies, so that use in patients is not delayed after provincial funding decisions.

**12:00PM – 1:00PM**     **Lunch & Networking**

MONDAY, SEPTEMBER 22, 2025

**1:00PM – 2:00PM**

### **Caring for an Aging Population: Policy and Advocacy for Brain Health**

Moderated by **Laveena Kamboj**, Senior Director, Value, Access & Policy, Eisai

Panelists:

- **Sudha Kutty**, Executive Vice-President, Evidence, Products, and Services at Canada's Drug Agency
- **Shawn Paron**, Chief Operating Officer, Alzheimer Society of Ontario
- **Jennie Z. Young**, Executive Director, Canadian Brain Research Strategy
- **Natalia Kusendova-Bashta**, Member of Provincial Parliament, Mississauga Centre
- **Zayna Khayat**, Health Futurist, Deloitte Canada, Life Sciences & Healthcare Practice

**Session Overview:** As Canada's population ages, brain health has become an urgent policy priority. This session will explore how policy can drive a shift from reactive to proactive brain health care for Canada's aging population. Using Alzheimer's disease as a case example, panelists will discuss how advocacy, policy reform, and government support can improve access to innovative therapeutics and support earlier intervention. Attendees will gain insights into how policy decisions and cross-sector collaboration can shape healthcare delivery, access, and long-term outcomes in brain health. Perspectives will be shared by a patient group leader, the architect of Canada's first national brain health research strategy, a Deloitte health futurist, a representative from Canada's Drug Agency (CDA-AMC), and Ontario's Minister of Long-Term Care.

**2:00PM – 3:00PM**

### **Maximizing the Value of PSP Data for Decision Making**

Moderated by **Belinda Yap**, Director, HEOR, Cencora – Innomar Strategies

Panelists:

- **Michael Duong, PhD**, Head of Innovation, Hoffmann-La Roche, Founding Board Member, CPHIN
- **Alison Oliver**, Senior Director, Customer Experience, Cencora – Innomar Strategies
- **Rob Chalmers**, Principal, ZS Associates
- **Dr. Farah Husein**, Director, Science and Methods at Canada's Drug Agency (CDA-AMC)
- **Daiana Matarazzo**, Head of Patient Services at Takeda Canada

**Session Overview:** Patient support programs (PSPs) are an integral part of a patient journey. They focus on enhancing care for patients with complex medical conditions treated with specialty medications, and the programs work in tandem with the healthcare system to fill the gaps in these patients' disease management needs. There is broad recognition by various stakeholders of the opportunity to leverage PSPs for RWE generation due to the multiple touchpoints with patients and direct communication with patients' healthcare teams and physicians, payers, and caregivers. With PSP infrastructure well-entrenched in Canada and building on the capability of PSPs to collect pan-Canadian data, an initiative led by the Canadian Personalized Healthcare Innovation Network (CPHIN) has focused on elevating PSP into a robust source of RWE for decision making. The first milestone of this collaborative effort was completed recently with the successful publication of a white paper outlining the "PSP Real World Readiness Framework". This session will present an update on progress by the CPHIN team since the publication of the PSP framework. This will be followed by perspectives from the panelists made up of various healthcare system stakeholders; discussions will include how organizations can best apply the PSP framework to improve the quality of PSP data.

**3:00PM – 3:30PM**

### **Afternoon Break**

**3:30PM – 4:30PM**

### **The Evolution of the 'Big C': From Cancer to Cure**

Moderated by **Fred Horne**, Health Policy Consultant & Senior Advisor, 3Sixty Public Affairs

Panelists:

- **Dr. Farah Husein**, Director, Science and Methods at Canada's Drug Agency (CDA-AMC)
- **Lisa Machado**, Executive Director & Founder, Canadian CML Network
- **Dr. Marcus Butler**, Medical Oncologist, Princess Margaret Cancer Centre; Associate Professor, University of Toronto.
- **Scott Gavura**, Director, Provincial Drug Reimbursement Programs

**Session Overview:** This session will explore the concept of "cure" in oncology through the perspectives of patients, caregivers, providers, payers, and HTA bodies. Panelists will discuss how the perception of cure shapes expectations, influences decision-making, and impacts outcomes across the cancer care system. By examining these diverse viewpoints, the session will highlight both opportunities and challenges in framing cure within Canada's oncology landscape, offering insights into how this evolving concept may affect stakeholders across the continuum of care.

**4:30PM – 5:30PM    Student Oral Presentations**

- 4:30 pm – 4:45 pm, Martin Ho – Abstract # 24: **Measuring the impact of the substitution of innovator biologics with biosimilars on uptake and costs among Ontario Drug Benefit recipients**
- 4:45 pm – 5:00 pm, Lara Haidar – Abstract # 49: **No Cause for Concern: Early eGFR Decline Following SGLT2 Inhibitor Use in People with HIV Mirrors Trends of the General Population**
- 5:00 pm – 5:15 pm, Andrew Li – Abstract # 68: **Relative-age effect on ADHD diagnosis and pharmacologic treatment in children**
- 5:15 pm – 5:30 pm, Keeirah Raguram – Abstract # 3: **Fluoroquinolones and the associated risk of panic attacks: A systematic review and active-comparator restricted disproportionality analysis**

**5:30PM – 5:45PM    Closing Remarks**  
**Adam Haynes**, CAPT-ACTP President  
Lower Concourse Auditorium

**5:45PM – 6:30PM    Reception & Poster Exhibition**  
Drinks & Hors D'oeuvres



**Peggy Kee Award – Best Poster**  
You are invited to vote for the poster you feel is most deserving of the Peggy Kee Award.  
  
To cast your vote, simply scan the QR code and complete the voting form.



# DAY 2

TUESDAY, SEPTEMBER 23, 2025

7:00AM – 9:00AM

## Registration & Breakfast

Lower Concourse Auditorium Foyer

9:00AM – 9:15AM

## Welcome to Day 2: 2025 CAPT-ACTP Conference

**Adam Haynes**, CAPT-ACTP President

Lower Concourse Auditorium

9:15AM – 10:15AM

## Patient Impact in CDA-AMC Reimbursement Reviews: How Can We Build on Progress to Date?

Moderated by **Bill Dempster**, President, 3Sixty Public Affairs

Panelists:

- **Deirdre DeJean**, Lead, Health Technology Assessment (HTA) and Deliberation at Canada's Drug Agency
- **Gail Attara**, Chief Executive Officer & Co-Founder, Gastrointestinal Society
- **Jessy Ranger**, Director, Patient Programs, Health Policy & Advocacy, Myeloma Canada
- **Bonnie Macfarlane**, Associate Director, HTA Submissions and Analytics at Johnson & Johnson

**Session Overview:** This panel will explore how collaboration between leaders from patient organizations, an HTA agency, and industry has influenced meaningful change in CDA-AMC's reimbursement review process, and how that progress can be sustained. Participants in this unique partnership will share the rationale behind the proposals investigated with CDA-AMC, their impact on CDA-AMC initiatives, and remaining opportunities, underscoring the importance of multi-stakeholder partnerships in advancing patient-centered HTA.

10:15AM – 10:45AM

## Morning Break

10:45AM – 11:45AM

## Early Detection and Better Access: Advancing the Continuum of Breast Cancer Care in Canada

Moderated by **Jefferson Tea**, CEO, Agilis Health

Panelists:

- **Dr. Anna Wilkinson**, GP Oncologist at The Ottawa Hospital
- **Dr. Sandy Sedhev**, Medical Oncologist, The Ottawa Hospital Cancer Centre
- **Kimberly Carson**, CEO Breast Cancer Canada

**Session Overview:** This symposium will bring together clinicians, advocates, and policymakers to stress the importance of early screening and better access to treatments in saving lives and improving outcomes. Speakers will highlight clinical evidence, equity challenges, and the role of advocacy in driving research and access. Attendees will leave with key takeaways and a call to action to support stronger screening programs, equitable access to innovative treatments, and collaborative partnerships across Canada.

11:45AM – 1:15PM

## Lunch, Awards, & Annual General Meeting

Lower Concourse Auditorium Foyer



**CAPT ACTP**  
Canadian Association for  
Population Therapeutics

MARS DISCOVERY DISTRICT  
SEPTEMBER 22-23, 2025  
WWW.CAPT-ACTP.CA

# DAY 2

TUESDAY, SEPTEMBER 23, 2025

1:15PM – 2:15PM

## **Building Canada's Rare Disease Strategy: Strengthening Canada with a Truly National Approach to Rare Diseases**

Moderated by **Gerry Jeffcott**, Senior Associate, 3Sixty Public Affairs

Panelists:

- **Durhane Wong-Rieger**, President and CEO, Canadian Organization for Rare Disorders
- **Ian Stedman**, Associate Professor of Canadian Public Law and Governance at York University
- **Jo Kennelly**, Executive Chair & Co-Founder, Malaika Vx Inc.
- **Rob Woolstencroft**, Head of Market Access, Alexion Pharmaceuticals, Inc.

**Session Overview:** Canada faces both economic pressures and critical gaps in access to care for rare diseases, underscoring the need for more resilient and innovative approaches. This panel will examine current strategies—including Health Canada's national drugs for rare disease (DRD) strategy, Quebec's action plan, and other emerging initiatives—and explore how expertise scattered across the country can be better connected. Panelists will discuss the vision for a national, multi-stakeholder action plan that ensures every patient, regardless of location, can access the best expertise and publicly funded treatments, setting the stage for the next phase of Canada's rare disease strategy.

2:15PM – 2:30PM

## **Closing Remarks**

**Jason R. Guertin**, CAPT-ACTP President-Elect

For questions about abstracts, registration, accommodations, or other conference details, please contact [admin@capt-actp.ca](mailto:admin@capt-actp.ca). Additional information is also available on the CAPT-ACTP website at [www.capt-actp.ca](http://www.capt-actp.ca).

**Access the abstract booklet and more by scanning the QR code below.**





# Thank you SPONSORS

## PLATINUM



## GOLD



## SILVER



## BRONZE



## RUBY



**CAPT ACTP**  
Canadian Association for  
Population Therapeutics

MARS DISCOVERY DISTRICT  
SEPTEMBER 22-23, 2025  
[WWW.CAPT-ACTP.CA](http://WWW.CAPT-ACTP.CA)